8 European Projects Found
Searched on 125080 European Projects
FINISHED
An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)
Start date: Jan 1, 2016, End date: Dec 31, 2021,
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Read Project
43
Partners Participants
FINISHED
Educational Network in Ocular Drug Delivery and Therapeutics (OcuTher)
Start date: Nov 1, 2016, End date: Oct 31, 2020,
Ocular drug development has transformed from niche area to a major field in drug development in which many companies, including European big pharma has entered recently. Ocular drug development is a unique field in terms of drug targets and end-points of activity, local drug administration routes, tissue barriers and pharmacokinetics, drug delivery and formulation challenges and local toxicity iss ...
Read Project
9
Partners Participants
FINISHED
Oral biopharmaceutics tools (ORBITO)
Start date: Oct 1, 2012, End date: Sep 30, 2017,
The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project
28
Partners Participants
FINISHED
Treatment of Adrenal Insufficiency in neonates- Development of a Hydrocortisone Preparation for the treatment of Adrenal Insufficiency in neonatesand infants (TAIN)
Start date: Dec 1, 2011, End date: Nov 30, 2016,
The aim of TAIN is to develop a neonatal formulation of hydrocortisone, a drug included in the EMA priority list that needs specific evaluation in the age range 0 – 2 years (neonates & infants). Hydrocortisone is an essential glucocorticoid hormone used as replacement therapy for the treatment of congenital and acquired adrenal insufficiency as well playing an important therapeutic role in oncolog ...
Read Project
8
Partners Participants
FINISHED
Drug Disease Model Resources (DDMORE)
Start date: Mar 1, 2011, End date: Aug 31, 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project
28
Partners Participants
FINISHED
Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)
Start date: Jan 1, 2011, End date: Dec 31, 2015,
"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Read Project
17
Partners Participants
FINISHED
Neuroscience on Barriers in Development (NEUROBID)
Start date: Jan 1, 2010, End date: Dec 31, 2013,
"Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to €386 billion (1). Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe’s total disease burden (1). In the treatment of neurological disease, the blood brain barrier (BBB) still represents an obstacle for the delivery of drugs to the brain and thus a ...
Read Project
10
Partners Participants
FINISHED
Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics (Predict-IV)
Start date: May 1, 2008, End date: Oct 31, 2013,
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early develo ...
Read Project
